| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Apollon Formularies PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0005 |
| 52 Week High | €0.001 |
| 52 Week Low | €0.0005 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -50.00% |
| 1 Year Change | 0% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 73R | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | -0.2% |
| 1Y | 0% | -21.9% | 2.0% |
Return vs Industry: 73R exceeded the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 73R underperformed the German Market which returned 3.9% over the past year.
Price Volatility
| 73R volatility | |
|---|---|
| 73R Average Weekly Movement | 14.4% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 73R's share price has been volatile over the past 3 months.
Volatility Over Time: 73R's weekly volatility has decreased from 61% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Stephen Barnhill | www.apollon.org.uk |
Apollon Formularies PLC operates as a medical cannabis pharmaceutical company. It offers hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products, such as cannabis oil vape, oral tincture, and perscribed capsules under the Apollon NAUSEA, Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER names. Apollon Formularies PLC was founded in 2014 and is based in Douglas, the United Kingdom.
Apollon Formularies PLC Fundamentals Summary
| 73R fundamental statistics | |
|---|---|
| Market cap | €385.60k |
| Earnings (TTM) | -€1.23m |
| Revenue (TTM) | €426.26k |
0.0x
P/S Ratio0.0x
P/E RatioIs 73R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 73R income statement (TTM) | |
|---|---|
| Revenue | UK£362.72k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£362.72k |
| Other Expenses | UK£1.41m |
| Earnings | -UK£1.05m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 73R perform over the long term?
See historical performance and comparison